Save
A randomized, double-blind, parallel group study to compare the safety and efficacy of Arbaclofen Extended Release Tablets to placebo and baclofen for the treatment of spasticity in patients with multiple sclerosis
Author(s): ,
D Kantor
Affiliations:
Kantor Neurology, Coconut Creek, FL
,
S.F Hunter
Affiliations:
Advanced Neurosciences Institute, Franklin, TN
,
A Dentiste
Affiliations:
Osmotica Pharmaceuticals, Marietta, GA, United States
,
M Aikman
Affiliations:
Osmotica Pharmaceuticals, Marietta, GA, United States
,
P Tyle
Affiliations:
Osmotica Pharmaceuticals, Marietta, GA, United States
S Kaba
Affiliations:
Osmotica Pharmaceuticals, Marietta, GA, United States
ECTRIMS Online Library. Kantor D. Sep 15, 2016; 146983; 128
Daniel Kantor
Daniel Kantor
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Discussion Forum (0)
Rate & Comment (0)

Abstract: 128

Type: Oral

Abstract Category: Therapy - symptomatic - Treatment of specific symptoms

Objective: To compare the efficacy and safety of Arbaclofen Extended Release Tablets (AERT) to placebo and baclofen over 12 weeks of treatment in patients with spasticity due to multiple sclerosis (MS).

Background: Spasticity is common in MS and is associated with significant morbidity. The standard treatment is oral administration of baclofen, a γ-aminobutyric acid-b (GABA-b) receptor agonist. Baclofen is a racemic mixture and its efficacy is thought to be due to the R-enantiomer (arbaclofen). Therapeutic doses of baclofen can cause CNS side effects and decreased adherence and tolerability. AERT can reduce dosing frequency and adverse events.

Design/Methods: This was a multicenter, randomized, double blind, active and placebo controlled parallel group study in adults with spasticity due to MS. The study compared AERT 20 mg BID with baclofen tablets 20 mg QID and matching placebo. The dose was titrated over 4 weeks followed by a 12-week maintenance period. The co-primary endpoints were the mean changes in Total Numeric-transformed Modified Ashworth Scale (TNmAS) and Clinician Global Impression of Change (CGIC) at the end of the maintenance period.

Results: Of 354 randomized subjects, 59.0% had relapsing remitting and 36.7% had secondary progressive MS. The average baseline TNmAS score was 7.78. TNmAS and CGIC were statistically significant in favor of AERT group compared with placebo, while differences between AERT and baclofen were not statistically significant. MS Spasticity Scale (MSSS-88) showed a statistically significant improvement in AERT group compared with placebo. Epworth Sleepiness Scale (ESS) showed a statistically significant increase in sleepiness in the baclofen group, but not in the AERT group compared to placebo. Drowsiness and dizziness were less frequent in AERT group compared with baclofen.

Conclusions: This study demonstrated that AERT administered twice a day was efficacious, safe, and better tolerated than baclofen in MS patients with spasticity.

Disclosure: Study supported by Osmotica Pharmaceutical.

Dr. Kantor has received personal compensation for activities with Avanir, Genzyme, Biogen Idec, Novartis, Questcor, Teva, Depomed, Osmotica, and Allergan. Dr. Hunter has received research support from Genzyme/Sanofi. Dr. Dentiste has received personal compensation for activities with Osmotica as an employee. Dr. Aikman has received personal compensation for activities with Osmotica as an employee. Dr. Kaba has received personal compensation for activities with Osmotica Pharmaceutical as an employee.

Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings